Hubei Goto Biopharm Group Co., Ltd. (SHE:300966)

Market Cap	2.75B +8.4%
Revenue (ttm)	650.05M +7.4%
Net Income	-95.05M
EPS	-0.82
Shares Out	114.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.05 (0.17%)
Ex-Dividend Date	Jul 16, 2026

Volume	1,614,200
Open	24.60
Previous Close	24.08
Day's Range	23.50 - 24.60
52-Week Range	18.44 - 32.58
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Hubei Goto Biopharm Group

Hubei Goto Biopharm Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other materials. The company was formerly known as Hubei Goto Biopharm Co.,Ltd. and changed its name to Hubei Goto Biopharm Group Co., Ltd. in June 2026. Hubei Goto Biopharm Group Co., Ltd. was founded in 2006 and is based in Xiangyang, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 893
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300966

Financial Performance

In 2025, Hubei Goto Biopharm Group's revenue was 606.18 million, an increase of 12.97% compared to the previous year's 536.60 million. Losses were -73.36 million, 165.9% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error